Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Austin, Texas

7 studies are recruiting for non-small cell lung cancer (nsclc) in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

   A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology-Austin Central, Austin, Texas

   Locations

   259 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07361497 on ClinicalTrials.gov

2. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

   TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Austin, Texas

   Locations

   206 in total

   Run by

   AstraZeneca

   See if you can join NCT07291037 on ClinicalTrials.gov

3. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Austin, Austin, Texas

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

4. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #46, Austin, Texas

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

5. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

   IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants wi…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   NEXT Texas LLC - Austin, Austin, Texas

   Locations

   11 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07540572 on ClinicalTrials.gov

6. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

   The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin, Texas

   Locations

   33 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT07154706 on ClinicalTrials.gov

7. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

   Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas at Austin, Austin, Texas

   Locations

   21 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT05379985 on ClinicalTrials.gov